APL is distinct from other types of leukemia due to its unique genetic mutation and clinical presentation. Unlike other forms of acute myeloid leukemia, APL responds exceptionally well to targeted therapies like ATRA and ATO. Additionally, the risk of severe bleeding and clotting complications is higher in APL compared to other leukemias.
